本文選題：S-腺苷高半胱氨酸水解酶(SAHH) + 高半胱氨酸(Hcy)　； 參考：《濟南大學(xué)》2017年碩士論文

【摘要】：當(dāng)體內(nèi)高半胱氨酸(Hcy)含量異常升高時會嚴(yán)重?fù)p害DNA的修復(fù)機制,誘導(dǎo)細(xì)胞的凋亡,進一步就會引起阿爾茨海默綜合癥(AD)、高半胱氨酸血癥、冠心病等。體內(nèi)Hcy的生成是由S-腺苷高半胱氨酸水解酶(S-adenosyl-homocysteine hydrolase,SAHH,E.C.3.3.1.1)催化S-腺苷高半胱氨酸(S-adenosylhomocystein,SAH)可逆水解生成腺苷(Ado)和Hcy。細(xì)胞中Hcy的生成只有水解SAH這唯一的一條代謝途徑,所以體內(nèi)Hcy含量的高低與SAHH蛋白酶有著密切的關(guān)系。本實驗旨在通過體外合成具有生物活性的SAHH,并且以該SAHH為研究基礎(chǔ)篩選得到可以抑制SAHH活性的抑制劑。此抑制劑的發(fā)現(xiàn)為有效地治療以及防止AD、高半胱氨酸血癥、冠心病等老年性疾病提供了新的、更有效的臨床治療方法。本論文通過基因克隆技術(shù)將sahh克隆到p Pic9k質(zhì)粒中構(gòu)建p PIC9K-sahh重組表達質(zhì)粒。該重組表達質(zhì)粒在限制性內(nèi)切酶——Bgl II的作用下酶切,酶切后目的基因通過電轉(zhuǎn)化的方法整合到畢赤酵母菌(P.pastoris)GS115的基因組。為了得到高抗性的轉(zhuǎn)化子,我們利用不同梯度濃度的G418遺傳霉素進行高抗性篩選,最終篩選得到高拷貝、高抗性的轉(zhuǎn)化子。將篩選到的高拷貝轉(zhuǎn)化子通過菌體的PCR進行擴增,鑒定其為陽性的轉(zhuǎn)化子。得到的陽性轉(zhuǎn)化子在1%的甲醇誘導(dǎo)下表達目的蛋白SAHH。隨后收集目的蛋白進行鎳柱純化,純化后的SAHH用DTNB定量的檢測其酶活,其比活為105 U/mg。為了進一步更好的了解此酶,本實驗還進行了酶促反應(yīng)動力學(xué)研究,探究得到該水解酶的K_m=21.8μM,V_(max)=22.9μM/min,最適的T=41℃,最適p H=6.5。我們利用Chem Mapper、Sci Finder Scholar等信息平臺來進行抑制劑的初步篩選。通過DTNB試劑檢測其酶活的變化情況來進一步的篩選,從而確定具有抑制效果的SAHH的抑制劑。最終成功篩選得到一種抑制效果相對較高的小分子化合物——4-(3-Hydroxyprop-1-en-1-yl)-2-methoxyphenol(松柏醇),其半抑制濃度(half maximal inhibitory concentration,IC_(50))為34.04nM。
[Abstract]:When the content of homocysteine (Hcy) in the body is abnormal, it can seriously damage the mechanism of DNA repair, induce cell apoptosis, and further cause Alzheimer's syndrome (AD), hypercysteinemia, coronary heart disease and so on. The formation of Hcy in vivo is from S- adenosine homocysteine hydrolase (S-adenosyl-homocysteine hydrolase, SAHH, E.C.3.3.1.1). S- adenosine (S-adenosylhomocystein, SAH) catalyzes the reversible hydrolysis of adenosine (Ado) and the formation of Hcy in Hcy. cells only a metabolic pathway that hydrolyzes SAH, so the level of Hcy in the body is closely related to the SAHH protease. This experiment aims to synthesize SAHH with biological activity in vitro AHH provides a new and more effective clinical therapy for the effective treatment and prevention of AD, hypercysteinemia, coronary heart disease and other senile diseases. This paper constructs a p PIC9K-sahh by cloning SAHH into the P Pic9k plasmid by gene cloning technology. Recombinant expression plasmid, the recombinant expression plasmid was cut under the action of restriction endonuclease, Bgl II, and the target gene was integrated into the genome of P.pastoris GS115 by electrical transformation. In order to obtain highly resistant transformants, we used the G418 geniin of different levels of G418 for high resistance screening. The highly copied and highly resistant transformants were screened. The screened high copy transformants were amplified by the PCR of the mycelium to identify the positive transformants. The positive transformants expressed the target protein SAHH. under 1% methanol and then collected the target protein for the purification of the nickel column. The purified SAHH was quantified by DTNB to detect the enzyme. In order to get a better understanding of the enzyme, the activity is 105 U/mg. to further understand the enzyme. This experiment has also carried out a kinetic study of enzymatic reaction, exploring the K_m=21.8 M of the hydrolase, V_ (max) =22.9 mu M/min, the optimum T=41 C, and the optimum P H=6.5.. TNB reagent detects the change of the enzyme activity to further screening, thus determining the inhibition effect of SAHH inhibitors. Finally, a relatively high inhibitory effect of small molecular compound, 4- (3-Hydroxyprop-1-en-1-yl) -2-methoxyphenol (pine cedar alcohol), its semi inhibitory concentration (half maximal inhibitory concentra) has been successfully screened. Tion, IC_ (50)) is 34.04nM.

【學(xué)位授予單位】：濟南大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R749.16

【參考文獻】

相關(guān)期刊論文 前10條

1 范愛德;;血漿高半胱氨酸對冠心病預(yù)后的影響分析[J];當(dāng)代醫(yī)學(xué);2014年32期

2 彭川漫;;冠狀動脈粥樣硬化性心臟病與血漿高半胱氨酸發(fā)病相關(guān)性研究[J];中外醫(yī)學(xué)研究;2014年23期

3 白雪;莊述娟;張冠慶;;Aβ蛋白對阿爾茲海默病的作用及藥物研究進展[J];醫(yī)學(xué)理論與實踐;2013年19期

4 周海燕;駱華;周卓;;高半胱氨酸對心腦血管疾病發(fā)生的臨床意義[J];心腦血管病防治;2012年03期

5 鄭嵋戈;阮志剛;劉靖;李國營;;β-淀粉樣蛋白的代謝機制[J];神經(jīng)解剖學(xué)雜志;2011年03期

6 馬煥云;;高半胱氨酸血癥與動脈粥樣硬化[J];新醫(yī)學(xué);2009年03期

7 熊怡淞;王愛華;耿紅蓮;陳軍;竺蓓;施巍宇;鄧燕;趙文靜;陳國飛;仲人前;;冠心病患者血清CRP和高半胱氨酸水平觀察[J];臨床檢驗雜志;2009年01期

8 金英玉;龐丹;辛?xí)悦?李潔;李琳;;高同型半胱氨酸血癥患者血液流變學(xué)指標(biāo)的變化與意義[J];中國微循環(huán);2008年01期

9 王楊;王金和;程佩蘭;;同型半胱氨酸的致病機理及臨床應(yīng)用[J];國際檢驗醫(yī)學(xué)雜志;2006年02期

10 王建國;血漿高半胱氨酸增高是2型糖尿病冠心病事件的獨立預(yù)兆因子[J];新醫(yī)學(xué);2004年05期

相關(guān)會議論文 前1條

1 龔家瑜;劉曉峰;蔡超前;高大啟;李洪林;;ChemMapper:基于分子相似性方法的靶標(biāo)藥理學(xué)及化學(xué)關(guān)系發(fā)現(xiàn)多功能計算平臺[A];2011年全國藥物化學(xué)學(xué)術(shù)會議——藥物的源頭創(chuàng)新論文摘要集[C];2011年

相關(guān)碩士學(xué)位論文 前1條

1 徐瑩穎;以LpxC為靶點的新型抗菌藥物計算機虛擬篩選、先導(dǎo)物優(yōu)化及活性研究[D];山東大學(xué);2012年

，

本文編號：1891194